Burden of illness for super-refractory status epilepticus patients

被引:23
|
作者
Beg, Jamil M. [1 ]
Anderson, Thomas D. [1 ]
Francis, Kevin [2 ]
Meckley, Lisa M. [2 ]
Fitzhenry, David [2 ]
Foster, Todd [2 ]
Sukhtankar, Susheel [2 ]
Kanes, Stephen J. [1 ]
Moura, Lidia M. V. R. [3 ]
机构
[1] Sage Therapeut Inc, 215 First St, Cambridge, MA 02142 USA
[2] Trinity Partners, Waltham, MA USA
[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
关键词
Epilepsy; Super-refractory status epilepticus; Cost; Resource utilization; Burden of illness; Hospitalization; CONVULSIVE STATUS EPILEPTICUS; ADMINISTRATIVE DATA; CASE-DEFINITION; ICD CODES; EPILEPSY; VALIDATION; MORTALITY; RECOMMENDATIONS; PREVALENCE; PREDICTORS;
D O I
10.1080/13696998.2016.1223680
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the US and to evaluate utilization of hospital resources by these patients. Methods: The Premier Hospital Database was utilized to estimate the number of SRSE cases based on hospital discharges during 2012. Discharges were classified as SRSE cases based on an algorithm using seizure-related International Classification of Diseases-9 (ICD-9) codes, Intensive Care Unit (ICU) length of stay (LOS), and treatment protocols (e.g. benzodiazepines, anti-epileptic drugs (AEDs), and ventilator use). Secondary analyses were conducted using more restrictive algorithms for SRSE. Results: A total of 6,325 hospital discharges were classified as SRSE cases from a total of 5,300,000 hospital discharges. Applying a weighting based on hospital characteristics and 2012US demographics, this projected to an estimated 41,156 cases of SRSE in the US during 2012, an estimated incidence rate of similar to 13/100,000 annually for SRSE in the US. Secondary analyses using stricter SRSE algorithms resulted in estimated incidence rates of similar to 11/100,000 and 8/100,000 annually. The mean LOS for SRSE hospitalizations was 16.5 days (median =11; interquartile range [IQR]=6-20), and the mean ICU LOS was 9.3 days (median =6; IQR =3-12). The mean cost of an SRSE hospitalization was $51,247 (median = $33,294; 95% CI = $49,634-$52,861). Limitations: The analysis uses ICD-9 diagnostic codes and claims information, and there are inherent limitations in any methodology based on treatment protocol, which created challenges in distinguishing with complete accuracy between SRSE, RSE, and SE on the basis of care patterns in the database. Conclusion: SRSE is associated with high mortality and morbidity, which place a high burden on healthcare resources. Projections based upon the findings of this study suggest an estimated 25,821-41,959 cases of SRSE may occur in the US each year, but more in-depth studies are required.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 50 条
  • [1] Super-Refractory Status Epilepticus
    Mauricio Ruiz Cuero
    Panayiotis N. Varelas
    Current Neurology and Neuroscience Reports, 2015, 15
  • [2] Refractory and Super-refractory Status Epilepticus
    Samanta, Debopam
    Garrity, Lisa
    Arya, Ravindra
    INDIAN PEDIATRICS, 2020, 57 (03) : 239 - 253
  • [3] Super-refractory status epilepticus
    Bleck, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E470 - E470
  • [4] Refractory and Super-refractory Status Epilepticus
    Debopam Samanta
    Lisa Garrity
    Ravindra Arya
    Indian Pediatrics, 2020, 57 : 239 - 253
  • [5] Super-Refractory Status Epilepticus
    Cuero, Mauricio Ruiz
    Varelas, Panayiotis N.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2015, 15 (11)
  • [6] Defining the Health Economic Burden of Treatment for Super-Refractory Status Epilepticus Patients
    Beg, Jamil
    Anderson, Thomas
    Francis, Kevin
    Foster, Todd
    Meckley, Lisa
    Sukhtankar, Susheel
    Kanes, Steven
    Moura, Lidia
    NEUROLOGY, 2016, 86
  • [7] Esclicarbazepin in the treatment of patients with refractory and super-refractory status epilepticus
    Winter, Y.
    Mueller, A.
    Luessi, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 165 - 165
  • [8] Treatment of Refractory and Super-refractory Status Epilepticus
    Samhitha Rai
    Frank W. Drislane
    Neurotherapeutics, 2018, 15 : 697 - 712
  • [9] Management of refractory and super-refractory status epilepticus
    Erbguth, Frank
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2019, 114 (07) : 628 - 634
  • [10] Refractory and Super-Refractory Status Epilepticus—an Update
    Sara Hocker
    William O. Tatum
    Suzette LaRoche
    W. David Freeman
    Current Neurology and Neuroscience Reports, 2014, 14